Alven et Daphni mènent la série A de la biotech Generare
法国生物科技初创公司Generare近日宣布完成由Alven和Daphni共同领投的A轮融资，具体金额未公开。该公司专注于开发针对遗传性罕见病的基因疗法，本轮融资将用于加速其先导项目的临床前研究。
Generare由基因治疗领域资深专家于2021年创立，其技术平台旨在通过新型腺相关病毒载体，精准递送基因以治疗由单基因缺陷引起的疾病。目前，公司管线中针对特定神经肌肉疾病的项目已取得重要实验数据。
Alven合伙人表示：“Generare团队在载体工程方面的深厚经验令人印象深刻，其方法有望解决当前基因疗法面临的靶向性挑战。”Daphni投资负责人补充道，他们看好该平台在罕见病治疗领域创造临床价值的潜力。
此次融资反映了欧洲风险投资持续关注下一代基因编辑与递送技术。随着罕见病药物开发政策环境优化，专注于精准疗法的生物科技公司正获得更多资本支持。Generare计划在未来18个月内推进首个候选药物进入临床开发阶段。
French biotech startup Generare has secured a €5 million Series A funding round led by venture capital firms Alven and Daphni. The funding will accelerate the development of its proprietary platform for producing human milk proteins, aiming to transform infant nutrition and therapeutic applications.
Generare, founded in 2021, leverages precision fermentation technology to manufacture complex proteins identical to those found in human breast milk. This approach addresses critical limitations of existing infant formulas, which rely on bovine milk proteins that are structurally different and can be difficult for some infants to digest. The company's initial focus is on producing lactoferrin and alpha-lactalbumin, key proteins with demonstrated benefits for immune function and nutrient absorption.
The investment round attracted participation from existing shareholders, including business angels and Bpifrance, via its Digital Venture fund. Generare plans to allocate the new capital toward expanding its R&D capabilities, scaling its bioproduction processes, and initiating regulatory engagement for its products.
Co-founders Romainville and Lebreton, who bring backgrounds in bioprocess engineering and business development from the biopharma sector, emphasize the platform's potential beyond infant nutrition. Their long-term vision includes applying these high-purity proteins to medical nutrition and specific therapeutic markets.
The investment underscores a growing VC interest in European biotech and food-tech alternatives. Alven and Daphni cite Generare's scientific approach, scalable technology, and addressable market as key factors in their decision to lead the round. The startup now joins a competitive landscape of companies using fermentation to create novel food ingredients, with a distinct focus on replicating the biological benefits of human milk.
L’article Alven et Daphni mènent la série A de la biotech Generare est apparu en premier sur Maddyness - Le média pour comprendre l'économie de demain.
法国生物科技初创公司Generare完成A轮融资，由Alven和Daphni领投，用于推进其基于人工智能的药物发现平台。
Generare — 法国生物科技公司，开发AI驱动的药物发现平台。
Alven — 法国风险投资公司，专注于早期科技初创企业。
Daphni — 欧洲风险投资公司，投资于数字和科技公司。
[Monitor] — AI在生物制药领域的应用持续获得资本关注，但技术商业化路径长。